Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Zeke Capital Advisors LLC

Zeke Capital Advisors LLC raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 46.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,945 shares of the medical research company’s stock after purchasing an additional 3,133 shares during the quarter. Zeke Capital Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,888,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Schroder Investment Management Group raised its holdings in Thermo Fisher Scientific by 28.1% in the 4th quarter. Schroder Investment Management Group now owns 1,103,685 shares of the medical research company’s stock valued at $209,568,000 after acquiring an additional 242,062 shares during the last quarter. Americafirst Capital Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at $876,000. Rockland Trust Co. raised its holdings in shares of Thermo Fisher Scientific by 7.3% in the 4th quarter. Rockland Trust Co. now owns 62,332 shares of the medical research company’s stock valued at $11,836,000 after purchasing an additional 4,221 shares in the last quarter. Huntington National Bank raised its stake in Thermo Fisher Scientific by 2.4% during the 3rd quarter. Huntington National Bank now owns 195,348 shares of the medical research company’s stock worth $36,959,000 after acquiring an additional 4,655 shares in the last quarter. Finally, Barrett Asset Management LLC raised its stake in Thermo Fisher Scientific by 7.8% during the 3rd quarter. Barrett Asset Management LLC now owns 101,620 shares of the medical research company’s stock worth $19,227,000 after acquiring an additional 7,335 shares in the last quarter. 87.67% of the stock is currently owned by institutional investors.

How to Become a New Pot Stock Millionaire

Thermo Fisher Scientific stock opened at $205.56 on Friday. The stock has a market capitalization of $85,121.98, a P/E ratio of 22.35, a price-to-earnings-growth ratio of 1.55 and a beta of 1.15. Thermo Fisher Scientific Inc. has a 12-month low of $151.74 and a 12-month high of $226.44. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.34 and a quick ratio of 0.92.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $2.79 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.66 by $0.13. Thermo Fisher Scientific had a return on equity of 16.01% and a net margin of 10.64%. The firm had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $5.72 billion. During the same period in the previous year, the business posted $2.41 EPS. The company’s quarterly revenue was up 22.1% compared to the same quarter last year. sell-side analysts predict that Thermo Fisher Scientific Inc. will post 10.83 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, April 16th. Shareholders of record on Thursday, March 15th will be given a dividend of $0.17 per share. The ex-dividend date of this dividend is Wednesday, March 14th. This represents a $0.68 dividend on an annualized basis and a yield of 0.33%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. Thermo Fisher Scientific’s dividend payout ratio is 7.17%.

TMO has been the topic of a number of research analyst reports. Evercore ISI started coverage on shares of Thermo Fisher Scientific in a report on Wednesday, January 3rd. They set an “outperform” rating and a $220.00 price objective on the stock. BTIG Research initiated coverage on shares of Thermo Fisher Scientific in a research report on Friday, January 5th. They issued a “buy” rating and a $230.00 price objective for the company. Zacks Investment Research downgraded shares of Thermo Fisher Scientific from a “hold” rating to a “sell” rating in a research note on Thursday, January 11th. Leerink Swann reiterated an “outperform” rating and set a $239.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Thursday, February 1st. They noted that the move was a valuation call. Finally, Barclays increased their price objective on shares of Thermo Fisher Scientific from $225.00 to $245.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Two equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $221.43.

In related news, CEO Marc N. Casper sold 40,000 shares of the stock in a transaction on Thursday, March 22nd. The stock was sold at an average price of $210.16, for a total value of $8,406,400.00. Following the sale, the chief executive officer now owns 334,622 shares in the company, valued at approximately $70,324,159.52. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Gregory J. Herrema sold 33,327 shares of the stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $219.70, for a total value of $7,321,941.90. Following the transaction, the senior vice president now owns 60,471 shares in the company, valued at approximately $13,285,478.70. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 88,827 shares of company stock valued at $19,012,672. Insiders own 0.49% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Zeke Capital Advisors LLC” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/04/07/thermo-fisher-scientific-inc-tmo-position-raised-by-zeke-capital-advisors-llc.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply